Leucovorin is a 5-formyl derivative of folic acid, used in the biochemical reactions without having to undergo reduction. Leucovorin is FDA indicated after high dose methotrexate therapy in osteosarcoma, to decrease the toxic effects of methotrexate or to counter the toxic effects of folate antagonists. Leucovorin is also occasionally an alternative agent used in the treatment of megaloblastic anemia when oral intake of folic acid is not possible. Leucovorin can prolong survival in patients when used in combination with 5-fluorouracil for the palliative treatment of colon cancer.
Off-label uses include as neoadjuvant treatment in bladder cancer, as a cofactor in methanol toxicity, in the treatment of advanced esophageal cancer, advanced gastric cancer, advanced pancreatic cancer, prevention of hematological toxicity of pyrimethamine in patients with AIDS and the treatment of ectopic pregnancy (along with methotrexate).
Leucovorin was initially known as "citrovorum factor" when researchers discovered it in 1948; they found it to be an essential cofactor for the growth of Leuconostoc citrovorum, a lactic acid bacterium. The FDA approved leucovorin in 2002, and the levo isomer leucovorin received approval in the year 2008 during a shortage of leucovorin.
Clinical manifestations of methotrexate toxicity include nausea, vomiting, diarrhea, stomatitis, mucositis, esophagitis, elevated hepatic enzymes, rash, renal failure, myelosuppression, acute lung injury, hypotension, tachycardia, and neurologic dysfunction. Toxic effects may occur hours to days to weeks after methotrexate overdose or administration.
Methotrexate is a folate antagonist that works by inhibiting the dihydrofolate reductase enzyme in cells. Leucovorin is a folate derivative that does not need to undergo reduction by the enzyme dihydrofolate reductase for utilization in various one-carbon transfer reactions in the body, such as DNA synthesis.
In contrast, leucovorin can also enhance the therapeutic effect and toxicity of 5 fluoropyrimidines, such as 5-fluorouracil, by increasing the binding of the drug to thymidylate synthase.
The onset of action is less than 5 minutes for intravenous dosing and 10-20 minutes and 20 to 30 minutes for intramuscular and oral administration, respectively. Leucovorin rapidly absorbs after oral administration; however, for doses of more than 25 mg, the absorption is saturated in the gut.
Leucovorin is excreted by the kidneys mainly as 10-formyl tetrahydrofolate and 5,10-methenyl tetrahydrofolate.
Leucovorin administration is by oral, intramuscular, or intravenous routes. Intravenous dosing is preferable in the presence of vomiting or malabsorption.
In the setting of methotrexate toxicity, intravenous dosing is preferred and should start immediately. Methotrexate becomes increasingly polyglutamated; the longer it stays in the cell, the polyglutamated methotrexate stays in the nucleus and is less susceptible to reversal with leucovorin . Monitoring the levels of methotrexate is recommended to determine the appropriate dosage and duration for leucovorin rescue therapy. Dosing may require alteration to account for renal insufficiency, dehydration, and third spacing.
When used as a part of chemotherapeutic regimens, leucovorin is not administered along with methotrexate. It is usually administered 24 hours after a course of methotrexate. Tissue toxicity may be permanent if leucovorin therapy gets delayed beyond 40 hours. It is not uncommon for methotrexate to be administered intrathecally, for example, in the presence of leptomeningeal carcinomatosis. Leucovorin rescue must not be administered intrathecally and may be fatal if administered by this route. Elimination of methotrexate from the cerebrospinal fluid (CSF) occurs by slow systemic diffusion and can be countered by intravenous methotrexate. Monitoring the level of methotrexate is recommended.
Leucovorin enhances the binding of 5-fluorouracil, and when administering both together, a lower dosage of 5-fluorouracil is necessary. Leucovorin administration usually takes place in the middle of or after the dose of fluorouracil regimen.
Leucovorin enhances the effects of 5-fluorouracil and may cause toxicity.
Folic acid in large quantities has been shown to counteract the pharmacological actions of antiepileptics such as primidone, phenobarbital, and phenytoin.
When leucovorin has been used concomitantly during the treatment of Pneumocystis jirovecii with trimethoprim-sulfamethoxazole (TMP-SMX), higher rates of treatment failure and morbidity have been reported.
The effects of leucovorin in pregnancy have not been the object of study. Leucovorin was a category C drug under the prior FDA system for categorizing medications in pregnancy. It is not known whether leucovorin gets excreted in breast milk. Caution is necessary when treating patients that are nursing with leucovorin as it may get excreted in breast milk.
If the clinician is using leucovorin alone to treat megaloblastic anemia, they must rule out B12 deficiency. Treating patients that are deficient in vitamin B12 with leucovorin may reverse the megaloblastic anemia; however, it will worsen the neurological manifestations of B12 deficiency.
In the setting of inadvertent methotrexate overdose, leucovorin must start as soon as possible; 10 mg/m^2 must be administered every 6 hours till the concentration of serum methotrexate falls below 10^-8 M on the methotrexate assay. The levels of serum methotrexate require monitoring once every 24 hours until the level falls below the threshold, and renal function must be monitored with daily checks of the serum creatinine levels. If the serum creatinine rises by more than 50% over the previous day's baseline or if the methotrexate one day after admission level is measured to be greater than 5 x 10^-6 M or serum methotrexate value at two days is greater than 9 x 10^-7 M, the dose of leucovorin should get increased to 100 mg/m2 administered intravenously till the serum methotrexate value falls below 10^-8 moles. Hydration is essential, and the team should start a sodium bicarbonate drip; the sodium bicarbonate dose gets titrated to maintain a urinary pH above 7.0.
For patients receiving leucovorin rescue after high dose methotrexate therapy, methotrexate and serum creatinine levels require monitoring at least once a day. Hydration and urinary alkalinization are essential. Leucovorin must continue till the methotrexate level falls below 0.05 micromolar. If delayed excretion is suspected or if raised creatinine levels appear, the dose of leucovorin must increase.
Patients receiving leucovorin along with 5-fluorouracil should have monitoring of serial complete blood counts with differential counts. The CBC and differential must be obtained after the first two rounds of chemotherapy and repeated once a week. Counts should get repeated after courses until reaching the lowest anticipated WBC count. Routine monitoring of liver function tests (LFTs) and serum electrolytes should take place before each course. In the presence of severe stomatitis, gastrointestinal toxicity, a WBC nadir of 1000 to 1900/ mm^3, or a platelet nadir 25000 to 75000/mm^3, the dose is decreased by 20%. In the presence of severe gastrointestinal toxicity, a WBC count below 1000/mm^3, or a platelet count less than 25000/mm^3, the dose must decrease by 30%. If none occurs during a course, the dose of leucovorin and fluorouracil may increase by ten percent.
When administered for folic acid deficiency, up to 1 mg per day can be administered intramuscularly. Serum levels of leucovorin do not require checking. Reticulocyte counts measure the response to treatment, and serial hemoglobin measurements, measurement of indirect bilirubin, LDH, serum iron, and potassium levels can be considered.
When administered along with fluorouracil, the following side effects can occur.
Leucovorin is a useful drug used in the setting of chemotherapy and methotrexate overdose.
Care of patients that are undergoing combination chemotherapy with leucovorin can be challenging and requires an interprofessional team of nurses, pharmacists, and physicians from different specialties. It is useful to know the symptoms of the toxicity of methotrexate. Early recognition of toxicity and early institution of treatment can reduce adverse outcomes.
When the clinician initiates leucovorin, they will do well to consult with the pharmacist to ensure proper dosing, the absence of potential interactions, and review the adverse events and corrective actions. Dosing and administration will fall to nursing; they must also be well-informed regarding early signs of adverse reactions, and keep the team informed on patient tolerance and therapeutic progress. If any issues become apparent, the nursing staff should promptly involve the pharmacy and the clinicians for corrective action. These interprofessional actions will optimize leucovorin therapy results while minimizing adverse effects. [Level 5]
|||Mishima H,Ikenaga M,Tsujinaka T,Yasui M,Kashiwazaki M,Miyazaki M,Hirao M,Fujitani K,Nakamori S, [FOLFOX]. Gan to kagaku ryoho. Cancer [PubMed PMID: 16835479]|
|||Barceloux DG,Bond GR,Krenzelok EP,Cooper H,Vale JA, American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. Journal of toxicology. Clinical toxicology. 2002; [PubMed PMID: 12216995]|
|||Al-Batran SE,Hartmann JT,Probst S,Schmalenberg H,Hollerbach S,Hofheinz R,Rethwisch V,Seipelt G,Homann N,Wilhelm G,Schuch G,Stoehlmacher J,Derigs HG,Hegewisch-Becker S,Grossmann J,Pauligk C,Atmaca A,Bokemeyer C,Knuth A,Jäger E, Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Mar 20; [PubMed PMID: 18349393]|
|||Conroy T,Desseigne F,Ychou M,Bouché O,Guimbaud R,Bécouarn Y,Adenis A,Raoul JL,Gourgou-Bourgade S,de la Fouchardière C,Bennouna J,Bachet JB,Khemissa-Akouz F,Péré-Vergé D,Delbaldo C,Assenat E,Chauffert B,Michel P,Montoto-Grillot C,Ducreux M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine. 2011 May 12; [PubMed PMID: 21561347]|
|||Hayes MS,Ward MA,Slabaugh SL,Xu Y, Lessons from the leucovorin shortages between 2009 and 2012 in a medicare advantage population: where do we go from here? American health [PubMed PMID: 25237422]|
|||Widemann BC,Adamson PC, Understanding and managing methotrexate nephrotoxicity. The oncologist. 2006 Jun; [PubMed PMID: 16794248]|
|||Fabre I,Fabre G,Goldman ID, Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer research. 1984 Aug; [PubMed PMID: 6204743]|
|||Jardine LF,Ingram LC,Bleyer WA, Intrathecal leucovorin after intrathecal methotrexate overdose. Journal of pediatric hematology/oncology. 1996 Aug; [PubMed PMID: 8689347]|
|||Florit-Sureda M,Conde-Estévez D,Vidal J,Montagut C, Hypersensitivity reaction caused by folinic acid administration: a case report and literature review. Journal of chemotherapy (Florence, Italy). 2016 Dec; [PubMed PMID: 26042586]|
|||Ureña-Tavera A,Zamora-Verduga M,Madrigal-Burgaleta R,Angel-Pereira D,Berges-Gimeno MP,Alvarez-Cuesta E, Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations. The Journal of allergy and clinical immunology. 2015 Apr; [PubMed PMID: 25457996]|